These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36862702)
1. Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials. Tian W; Zhang L; Liu X; Ma X; Wang R PLoS One; 2023; 18(3):e0282360. PubMed ID: 36862702 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074 [TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials. Zhong S; Qie S; Yang L; Yan Q; Ge L; Wang Z Medicine (Baltimore); 2017 Jul; 96(30):e7611. PubMed ID: 28746215 [TBL] [Abstract][Full Text] [Related]
5. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer? Tu C; Zheng F; Wang JY; Li YY; Qian KQ Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. Jin J; Teng C; Li T Drug Des Devel Ther; 2018; 12():475-480. PubMed ID: 29563772 [TBL] [Abstract][Full Text] [Related]
8. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials. Tian W; Guo Q; Fu D; Ma X; Wang R PLoS One; 2023; 18(12):e0295745. PubMed ID: 38127857 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. Tian W; Ding W; Kim S; Xu X; Pan M; Chen S Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141 [TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials. Jin SF; Fan ZK; Pan L; Jin LM Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Xiao BY; Wang BC; Lin GH; Li PC Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449 [TBL] [Abstract][Full Text] [Related]
16. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511 [TBL] [Abstract][Full Text] [Related]
17. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187 [TBL] [Abstract][Full Text] [Related]
18. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. Li Q; Yuan Z; Yan H; Wen Z; Zhang R; Cao B Clin Ther; 2014 Jul; 36(7):1054-63. PubMed ID: 24986485 [TBL] [Abstract][Full Text] [Related]
19. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data. Ying J; Chen J Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]